better late never upgrad outperform confid
pipelin momentum addit invest
abbott post fourth-quart result report revenu billion come roughli
million billion target compar oper basisexclud
amorevenu growth constant-curr nice model
growth vast major upsid versu model came epd million
diagnost million major relat estim aler
devic million ep high end manag guidanc
rang even ad spend
follow call follow-up manag upgrad share outperform
highlight upgrad includ
recent trend across busi segment appear sustain combin
synergi recent deal lead mid- high-single-digit sale growth
midteen earn growth one top-tier profil large-cap med tech
multipl ongoing/upcom product launch across busi segment
potenti repres multihundred-million-dollar sale opportun next
sever year see opportun product still front us
increment spend hundr million dollar support pipelin roll-out
new product develop year impli durabl growth invest start
pay dividend spend level taper creat earn leverag
flexibl capit alloc start manifest later year compani
quickli pay debt taken recent billion acquisit
drive higher share repurchas invest beyond
risk relat intern pediatr nutrit sale seem stabil
manag quickli implement improv within recent acquir aler
valuat remain reason despit sizabl gain stock last year sustain
midteen earn growth may drive multipl expans
return equiti ttm
abbott highli diversifi provid medic devic nutrit pharmaceut product
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
highlight view quarter includ
second quarter epd growth doubl digit bullish commentari end-market abbott
stabil nutrit includ china linger concern new legisl
new product continu gain traction across medic devic continu
on-going releas alin diagnost system outsid unit state provid consist
tailwind division perform sever year
posit commentari aler integr manag suggest integr gone warp speed
signific chang busi structur alreadi put place meanwhil stj synergi
track least million consist prior commentari
guidanc call organ currency-neutr revenu growth manag point high end
rang drive ep growth least midteen upsid potenti perform
integr synergi foreign exchang
valuat stock thought
last two year abbott undergon fairli signific chang busi structur shift invest
thesi away emerg market growth freedom acquir whatev want pipelin execut
bottom-lin integr stori combin slowdown intern pediatr nutrit busi
initi skeptic would result near-term revenu upsid said compani execut transit
high level intern risk stabil
look forward pipelin new product launch gain traction acceler top-lin growth
synergi larg transact appear play least well expect combin
believ gener stabl strong perform variou organ busi abbott set top-tier
revenu earn growth ad on-going de-lever flexibl bring capit alloc
discuss later year along hundr million dollar increment sale market spend
thank upsid perform lower tax rate durabl growth appear sound reason
along still quit reason valuat time ep believ upgrad stock time
still make sens despit strong move stock last sever month
diabet sale growth compar oper basi estim
primarili driven strong on-going sale freestyl libr believ vast major libr sale quarter
gener intern product launch domest decemb libr
intern patient instal base span countri full partial reimburs system avail
european countri manag suggest libr ad net patient per quarter larg outsid
unit state similar commentari given last quarter
believ abbott close million libr sale compar million estim product
gener estim inclus sale long term see libr potenti billion-plu franchis
driven growth domest new featur ad market adopt monitor product acceler note
libr one product launch manag expect invest sale market year
product launch unit state
manag reiter expect million million domest sale estim equat
roughli patient addit year instal base may smaller given patient churn
particularli without reimburs approv healthi ramp particularli limit commerci
reimburs start year view number patient add achiev given like invest
compani make throughout year
receiv commerci approv libr end abbott receiv medicar approv
product earli see note freestyl libr medicar approv come earlier expect
chang thesi detail approv under-penetrated market could drive sale
higher current anticip although believ medicar patient like benefit
alert alarm associ competit cgm product
libr low cost price structur potenti appeal larg type market strong adopt seen europ
date bolster confid product see strong adopt
research suggest sensor go roughli apiec though abbott run promot
save program place allow patient access three pack sensor total
believ price structur could appeal patient want need featur full blown
continu glucos monitor cgm provid see note lower estim reflect freestyl
libr impact chang may come posit long term detail
believ endocrinologist posit libr type devic rather type
devic lack alert alarm continu connect reader see note patient
diabet meet suggest strong interest cgm libr view type product
endocrinologist detail could prove market expans patient
flash/continu monitor devic today accord center diseas control roughli million
million peopl diagnos type diabet unit state believ libr could see
success adopt patient popul
believ larger factor domest libr adopt hing abbott abil establish commerci
reimburs contract research suggest compani gain ci
durabl medic equip dme coverag estim repres roughli million
million live coverag respect aetna aet dme coverag polici review soon
updat polici includ posit coverag libr could result anoth roughli million live
cardiac rhythm manag total sale increas compar oper basi domest
intern sale came expect million believ mainli
function progress abbott made regain share sinc approv launch mri-saf low-voltag
pacemak assur mri-saf pacemak tendril mri-saf pace lead februari approv mri-
safe ellips late septemb
gener lack mri-saf label entir crt portfolio competit crt-p launch affect
sale compani receiv mri-saf approv quadra assura mp crt-d anoth fortifi assura earli
januari allow begin regain share note market twice size pacemak market
billion make import market compani full year manag expect sale
low singl digit compar flat low singl digit expect last quarter
combin mri-saf crt-d pacemak approv coupl like crt-p mri-saf
approv later year allow abbott ramp recaptur share longer term near term
re-impl replac can lead opportun may headwind abbott given batteri
issu st jude face physician may avoid implant compani devic
model total revenu billion assum domest growth includ
benefit new mri-saf portfolio favor comparison especi first half year
neuromodul growth unit state compar estim roughli million
model intern revenu million estim growth oper model growth
compani face difficult comp core busi unit state follow year growth though
believ continu see market growth db annual modest sale model domest
growth first quarter growth
burst estim burst help abbott gain share domest estim compani hold roughli
billion market howev expect growth moder
annual initi product launch comp becom difficult
burst convers nan meet revolv around previous present clinic data
continu focu medial pathway discuss burst seen strong growth sinc launch late
estim abbott growth roughli though report growth rate may slow
believ abbott abl maintain gain share come year momentum new waveform
tonic continu climb see note thought north american neuromodul societi
nan meet la vega competit updat
drg abbott continu see posit uptak dorsal root ganglion drg stimul product use
treatment chronic region pain syndrom crp newer edit proclaim drg featur new
control longer batteri life mri approv upgrad featur enhanc patient experi
may provid like small benefit adopt
infin db believ domest sale abbot deep brain stimul db product total roughli million-
million abbott enter million deep brain stimul market octob thu
face difficult db comp throughout believ compani make good progress take share
largest competitor market outperform gain continu
near term
heart failur abbott receiv domest approv latest left ventricular assist devic lvad heartmat
short-term bridge-to-transpl btt /bridge-to-myocardi recoveri late august end third quarter
expect approv contribut overal domest growth compar oper basi quarter
allow market share captur expect compani may lost share medtron
hvad last quarter hvad receiv long-term destin therapi dt indic end septemb
hvad offer btt dt abbott pursu dt indic import histor
primari growth driver lvad market
nutrit stabil growth remain flat overal world-wide nutrit sale grew oper
quarter believ sale reacceler remain low singl digit overal expect market
remain competit near term manag clear call compani look improv outlook
reacceler growth come already-impl regul other
investments/strateg decis
pediatr nutrit oper quarter improv sequenti expect
continu busi outsid unit state dynam china stabil even improv
manag note see soft market condit sever countri middl east
southeast asia though believ market near turn point bottom becom less
year-over-year headwind lack visibl mani move piec oversea market channel
inventori level especi part china work inventori acquir new regul
put place januari gener macro environ continu move e-commerc make growth
difficult predict howev expect market outsid unit state grow low singl digit
domest sale pediatr segment grew oper quarter believ growth
unit state achiev throughout compani annual product launch drove solid
growth compani launch new product may continu drive above-market growth
adult nutrit post oper domest growth quarter follow declin last quarter
busi favor comparison compani annual roughli per quarter first
third quarter due softer demand privat label product gain traction market manag
remain focus acceler busi believ low-single-digit growth achiev also view
reason model world-wide sale growth full year
establish pharmaceut epd oper growth quarter line model come
comp key emerg market segment grew fuel double-digit growth india china
latin america geographi aid compani invest ad scale recent introduc product
portfolio emerg market geographi grew larg due time sale
manag felt comfort level growth go forward emerg market sever macro tailwind
includ age popul expand middl class grow healthcar system increas healthcar spend
though conced difficult us verifi growth remain someth black box view manag
estim growth reason high singl digit low doubl digit believ potenti expand
done last year go estim busi grow report line manag
commentari compani sever easi comp first half year growth rate somewhat lumpi
throughout year due year-over-year comparison second quarter repres easier comp
quarter affect india good servic tax tune million though full-year basi view
target achiev
diagnost fourth-quart compar oper revenu growth driven above-market share gain core
lab growth infecti diseas test adopt i-stat point care strong start respiratori season
overal appear anoth stabl quarter growth legaci diagnost busi confirm progress
stabil oper headwind aler
laboratori fourth-quart revenu growth compar oper basi healthi beat
target driven market share gain suspect fuel on-going launch
alin diagnost system outsid unit state product offer platform across clinic chemistri
immunoassay blood screen transfus hematolog molecular diagnost offer much need refresh
prior instrument roll-out multi-year process regulatori approv still need occur
natur contract accompani system placement mean market even
come renew given year believ alin necessarili complet game-chang
would surpris see instrument drive point share gain next sever year help
juic revenu growth segment
point oper growth basi point lower expect driven
continu uptak i-stat handheld system quarter result line mid- high-single-
digit point care end-market growth despit tougher comp fourth quarter full year
growth also line expect segment
molecular diagnost revenu quarter million compar oper growth slight miss
million estim growth remain somewhat mute compani continu exit certain product
line mainli unit state note compani show strong intern growth like aid
molecular diagnost instrument alin famili initi compet virolog also make
push sti market said alin system mdx appear signific share
gainer believ abl disrupt growth long-establish player like
outperform /cepheid roch rhhbi outperform
rapid diagnost aler revenu million beat target million back strong flu strep
sale well quick integr effort assumpt new product salesforc seem
oper side busi stabil bit abbott note quick fix issu
hinder growth stand-alon busi end manag point intern
oper challeng overal lack new product innov refresh point invest
abbott compani focu invest new product includ refresh sg
near term abl produc emerg sustain growth two three year though
quantifi
specif outlook aler asset compani expect sale slightli
billion larg line commentari last quarter net ep accret around view
commentari posit given amount work still need done come year
overal believ diagnost continu grow nice mid- high-single-digit rang line slightli
better end-market manag seem bullish opportun introduc new product refresh
exist instal base alin caution investor think diagnost becom driver outsiz growth
compani major alin type diagnost sale contain five-year contract incumb system
roughli retent rate mean market share chang per year abbott abl take even
growth like still mid- high-single-digit rang believ good enough help maintain
model updat updat model accord manag guidanc
note manag input full-year organ revenu growth littl basi point
favor foreign exchang impact gross margin somewhat sg somewhat around
impli oper margin contract restat basi take account chang pension account
standard oper margin would roughli flat
prior chang pension account roughli million net pension-rel incom account cog
sg line chang incom record non-operating incom adjust
chang oper margin would roughli versu abbott report flat oper margin
model line guidanc
manag note guidanc would impli basi point oper margin expans even
pension account chang howev due neg gross margin impact aler acquisit plan
reinvest expans like larg negat
sale increas sale estim billion compar previous billion
earn full-year earn per share estim previou estim
publish sale estim billion compar ep estim
